Search results for "thiazolidinediones"

showing 3 items of 33 documents

Non-glycemic effects of pioglitazone and incretin-based therapies.

2013

Atherosclerosis and cardiovascular events are highly prevalent and represent the major cause of mortality in patients with type 2 diabetes. Therefore, there is significant interest in the non-glycemic properties of anti-diabetic agents, particularly on those that are effective on cardiovascular risk factors. Thiazolidinediones and incretin-based therapies (IBTs) represent some of the most recent treatment options approved for the management of type 2 diabetes; these agents have shown important glycemic effects, as well as a number of non-glycemic effects. The latter include those on body weight, inflammation, hypertension and dyslipidemia, thus impacting the different components of the meta…

medicine.medical_specialtyAtherosclerosis cardiovascular events type 2 diabetes pioglitazone incretin-based therapiesClinical BiochemistryMEDLINEIncretinType 2 diabetesPharmacologyIncretinsDrug DiscoverymedicineHumansHypoglycemic AgentsIn patientIntensive care medicineGlycemicDyslipidemiasPharmacologyPioglitazonebusiness.industryBody Weightmedicine.diseaseCardiovascular DiseasesMolecular MedicineThiazolidinedionesMetabolic syndromebusinessPioglitazoneDyslipidemiamedicine.drug
researchProduct

A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes

2015

Contains fulltext : 152084.pdf (Publisher’s version ) (Open Access) BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of tre…

medicine.medical_specialtyDecision support systemEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]MEDLINEType 2 diabetesComorbidityHypoglycemiaGlucagon-Like Peptide-1 ReceptorBody Mass IndexEndocrinologyLife ExpectancyClinical ProtocolsInternal medicineHealth careReceptors GlucagonMedicineHumansHypoglycemic AgentsInsulinPrecision MedicineIntensive care medicineExpert TestimonyReimbursementComputingMilieux_MISCELLANEOUSGlycated HemoglobinDipeptidyl-Peptidase IV InhibitorsPioglitazonebusiness.industryDrug SubstitutionType 2 Diabetes MellitusMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Original ArticlesPrecision medicinemedicine.diseaseDecision Support Systems ClinicalHypoglycemiaMetformin3. Good healthEuropeMedical Laboratory TechnologyEndocrinologySulfonylurea CompoundsDiabetes Mellitus Type 2Drug Therapy CombinationThiazolidinedionesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Adipokines and Lipoproteins: Modulation by Antihyperglycemic and Hypolipidemic Agents

2014

Abstract Adipose tissue is an endocrine organ that secretes a number of hormones and metabolically active substances that impact energy metabolism and insulin sensitivity. These inflammatory markers are collectively referred to as adipocytokines, or adipokines. Adipose tissue's functional capacity and metabolic activity vary among individuals, thus partly explaining the incomplete overlap between obesity and the metabolic syndrome. The functional failure of adipose tissues results in changed energy delivery and impaired glucose consumption, triggering self-regulatory mechanisms to maintain homeostasis. Antihyperglycemic, hypolipidemic, antiobesity, and angiotensin II receptor blocker drugs …

medicine.medical_specialtyLipoproteinsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipokineAdipose tissueIncretinsNiacinAnti-Obesity AgentsInsulin resistanceAdipokinesInternal medicineInternal MedicineAnimalsHumansHypoglycemic AgentsInsulinMedicineHypolipidemic AgentsMetabolic Syndromebusiness.industryInsulinFibric AcidsEzetimibemedicine.diseaseLipidsMetforminGlucoseEndocrinologyAdipose TissueHypolipidemic AgentsAzetidinesThiazolidinedionesAnti-Obesity AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistanceMetabolic syndromebusinessHormoneMetabolic Syndrome and Related Disorders
researchProduct